nach oben

Drugs

Erschienen in:

01.03.2015 | Adis Drug Evaluation

Posaconazole: A Review of the Gastro-Resistant Tablet and Intravenous Solution in Invasive Fungal Infections

verfasst von: Kate McKeage

Erschienen in: Drugs | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Posaconazole (Noxafil^®) is a triazole antifungal agent with an extended spectrum of antifungal activity. It is approved for the prophylaxis of invasive fungal infections in patients with neutropenia or in haematopoietic stem cell transplant recipients undergoing high-dose immunosuppressive therapy for graft-versus-host disease, and for the treatment of fungal infections. The efficacy and good tolerability of posaconazole oral suspension administered three or four times daily is well established. However, in order to overcome pharmacokinetic limitations associated with the suspension, a new gastro-resistant tablet and intravenous (IV) solution were developed. This article reviews the pharmacokinetic properties of the new posaconazole formulations and briefly summarizes efficacy data relating to the suspension. The pharmacokinetic advantages of the posaconazole gastro-resistant tablet compared with the suspension formulation include less interpatient variability, better systemic availability enabling once-daily administration, and absorption that is unaffected by changes in gastric pH or motility; in addition the tablets may be taken with or without food. The posaconazole tablet achieves higher and more consistent mean plasma concentrations than the suspension and, therefore, it is the preferred option to optimize efficacy in the prophylaxis or treatment of invasive fungal disease. The posaconazole IV solution provides an option for these same indications in patients who are unable to receive oral formulations.

Neofytos D, Lu K, Hatfield-Seung A, et al. Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy. Diagn Microbiol Infect Dis. 2013;75:144–9.CrossRefPubMedCentralPubMed

Pagano L, Caira M, Candoni A, et al. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. Clin Infect Dis. 2012;55:1515–21.CrossRefPubMed

Ullmann AJ, Akova M, Herbrecht R, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012;18(Suppl 7):53–67.CrossRefPubMed

Mousset S, Buchheidt D, Heinz W, et al. Treatment of invasive fungal infections in cancer patients: updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2014;93:13–32.CrossRefPubMedCentralPubMed

Herbrecht R, Tissot F, Agrawal S, et al. 2013 Update of the ECIL guidelines for antifungal therapy in leukemia and HSCT patients (ECIL 5). European conference on infections in leukaemia. 2013.

Akan H, Antia VP, Kouba M, et al. Preventing invasive fungal disease in patients with haematological malignancies and the recipients of haematopoietic stem cell transplantation: practical aspects. J Microb Chemother. 2013;69(Suppl 3):iii5–15.

Li Y, Theuretzbacher U, Clancy CJ. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet. 2010;49(6):379–96.CrossRefPubMed

Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother. 2006;50(5):1881–3.CrossRefPubMedCentralPubMed

Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53:958–66.CrossRefPubMedCentralPubMed

10.

Krishna G, Ma L, Martinho M, et al. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother. 2012;56(8):4196–201.CrossRefPubMedCentralPubMed

11.

Fule R, Amin P. Hot melt extruded amorphous solid dispersion of posaconazole with improved bioavailability: investigating drug-polymer miscibility with advanced characterisation. Biomed Res Int. 2014. doi:10.1155/2014/146781.

12.

Frampton JE, Scott LJ. Posaconazole: a review of its use in the prophylaxis of invasive fungal infections. Drugs. 2008;68(7):993–1016.CrossRefPubMed

13.

Kwon DS, Mylonakis E. Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother. 2007;8:1167–78.CrossRefPubMed

14.

Lass-Flörl C. Triazole antifungal agents in invasive fungal infections: a comparative review. Drugs. 2011;71(18):2405–19.CrossRefPubMed

15.

Campoli P, Perlin DS, Kristof AS, et al. Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis. J Infect Dis. 2013;208(10):1717–28.CrossRefPubMedCentralPubMed

16.

Sheppard DC, Campoli P, Duarte RF. Understanding antifungal prophylaxis with posaconazole in hematology patients: an evolving bedside to bench story. Haematologica. 2014;99(4):603–4.CrossRefPubMedCentralPubMed

17.

European Medicines Agency. Noxafil 40 mg/mL oral suspension, 100 mg gastro-resistant tablets, and 300 mg concentrate for solution for infusion: summary of product characteristics. 2014. http://ec.europa.eu/health/documents/community-register/html/h320.htm. Accessed 22 Dec 2014.

18.

Krishna G, Martinho M, Chandrasekar P, et al. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy. 2007;27:1627–36.CrossRefPubMed

19.

Lipp H-P. Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. Br J Clin Pharmacol. 2010;70(4):471–80.CrossRefPubMedCentralPubMed

20.

Krishna G, AbuTarif M, Xuan F, et al. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy. 2008;28:1223–32.CrossRefPubMed

21.

Duarte RF, López-Jiménez J, Cornely OA, et al. Phase 1b study of new posaconazole tablet for the prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother. 2014;58:5758–65.CrossRefPubMed

22.

Cornely OA, Duarte RF, Haider S, et al. Phase 3 pharmacokinetics (PK) and safety study of posaconazole (POS) tablet in patients at risk for invasive fungal infection [abstract no. LB2966]. 23rd European congress of clinical microbiology and infectious diseases. 2013.

23.

Maertens J, Cornely OA, Ullmann AJ, et al. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob Agents Chemother. 2014;58:3610–7.CrossRefPubMedCentralPubMed

24.

Cornely OA, Haider S, Grigg A, et al. Phase 3 pharmacokinetics (PK) and safety study of posaconazole (POS) IV in patients (pts) at risk for invasive fungal infection (IFI) [abstract no. A-292]. 53rd interscience conference on antimicrobial agents and chemotherapy. 2013.

25.

Krishna G, Ma L, Martinho M, et al. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother. 2012;67(11):2725–30.CrossRefPubMedCentralPubMed

26.

Kersemaekers WM, van Iersel T, Nassander U, et al. Pharmacokinetics and safety study of posaconazole IV solution by peripheral administration in healthy subjects. Antimicrob Agents Chemother. 2014. doi:10.1128/AAC.04223-14.

27.

Brüggemann RJM, Alffenaar J-WC, Blijlevens NMA, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48:1441–58.CrossRefPubMed

28.

Kraft WK, Chang PS, van Iersel MLPS, et al. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother. 2014;58:4020–5.CrossRefPubMedCentralPubMed

29.

Lipp H-P. Posaconazole: clinical pharmacokinetics and drug interactions. Mycoses. 2011;54(Suppl 1):32–8.CrossRefPubMed

30.

Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7–14.CrossRefPubMed

31.

Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–59.CrossRefPubMed

32.

Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–47.CrossRefPubMed

33.

Shen Y, Huang X-J, Wang J-X, et al. Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study. Int J Clin Pharmacol Ther. 2013;51(9):738–45.CrossRefPubMed

34.

Kung HC, Johnson MD, Drew RH, et al. Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study. Cancer Med. 2014;3(3):667–73.CrossRefPubMedCentralPubMed

35.

Girmenia C, Frustaci AM, Gentile G, et al. Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. Haematologica. 2012;97(4):560–7.CrossRefPubMedCentralPubMed

36.

Peterson L, Ostermann J, Rieger H, et al. Posaconazole prophylaxis: impact on incidence of invasive fungal disease and antifungal treatment in haematological patients. Mycoses. 2013;56(6):651–8.CrossRefPubMed

37.

Vehreschild JJ, Ruping MJGT, Wisplinghoff H, et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother. 2010;65(7):1466–71.CrossRefPubMed

38.

Sánchez-Ortega I, Patiño B, Arnan M, et al. Clinical efficacy and safety of primary atnifungal prophylaxis with posaconazole vs itraconazole in allogenic blood and marrow transplantation. Bone Marrow Transplant. 2011;46:733–9.CrossRefPubMed

39.

40.

Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44:2–12.CrossRefPubMed

41.

Huang X, Wang F, Chen Y, et al. A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy. Future Microbiol. 2012;7(2):201–9.CrossRefPubMed

42.

Kim MM, Vikram HR, Kusne S, et al. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis. 2011;53(11):1060–6.CrossRefPubMed

43.

Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis. 2006;42:1398–403.CrossRefPubMed

44.

Vehreschild JJ, Birtel A, Vehreschild MJGT, et al. Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol. 2013;39(3):310–24.CrossRefPubMed

45.

Moton A, Krishna G, Wang Z. Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers. J Clin Pharm Ther. 2009;34(3):301–11.CrossRefPubMed

46.

Pettit NN, Steinbeck JL, Han Z, et al. Posaconazole (PCZ) tablet formulation therapeutic drug monitoring (TDM) and toxicity analysis [abstract no. A-702]. 54th interscience conference on antimicrobial agents and chemotherapy. 2014.

47.

Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56–93.CrossRefPubMed

48.

Vaes M, Hites M, Cotton F, et al. Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome. Antimicrob Agents Chemother. 2012;56(12):6298–303.CrossRefPubMedCentralPubMed

49.

Dolton MJ, Ray JE, Marriott D, et al. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother. 2012;56(6):2806–13.CrossRefPubMedCentralPubMed

50.

Percival KM, Bergman SJ. Update on posaconazole pharmacokinetics: comparison of old and new formulations. Curr Fungal Infect Rep. 2014;8(2):139–45.CrossRef

51.

Cattaneo C, Borlenghi E, Panzali A, et al. Impact of posaconazole prophylaxis on invasive fungal infection during acute myeloid leukemia induction therapy: correlation with posaconazole serum levels [abstract no. 3484]. 55th annual meeting and exposition of the american society of hematology. 2013.

52.

Döring M, Muller C, Johann PD, et al. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect Dis. 2012. doi:10.1186/1471-2334-12-263.

53.

Döring M, Blume O, Haufe S, et al. Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation. Eur J Clin Microbiol Infect Dis. 2014;33(4):629–38.CrossRefPubMedCentralPubMed

54.

Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother. 2006;50(2):658–66.CrossRefPubMedCentralPubMed

Titel: Posaconazole: A Review of the Gastro-Resistant Tablet and Intravenous Solution in Invasive Fungal Infections
verfasst von: Kate McKeage
Publikationsdatum: 01.03.2015
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 4/2015
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-015-0348-3

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

Vonoprazan: First Global Approval

Febuxostat: A Review of Its Use in the Treatment of Hyperuricaemia in Patients with Gout

Clinical Efficacy and Safety of Cilostazol: A Critical Review of the Literature

Preventive Analgesia and Novel Strategies for the Prevention of Chronic Post-Surgical Pain

Fluticasone Furoate/Vilanterol: a Review of Its Use in Patients with Asthma

Naloxegol: A Review of Its Use in Patients with Opioid-Induced Constipation